Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01117636 · ClinicalTrials.gov registry record · Phase 3
Evaluate Analgesic Efficacy of Fast Release Aspirin
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 514
- Enrollment target
NCT01117636 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 514 participants.
The verdict
NCT01117636, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 514 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the analgesic efficacy of a single, oral dose of fast release aspirin tablets, 1000 mg (2 x 500 mg) compared to regular aspirin tablets, 1000 mg (2 x 500 mg) and placebo in subjects with postsurgical dental pain.
Interventions
- DRUG Placebo
- DRUG Acetylsalicylic Acid (Aspirin, BAYE4465)
- DRUG Acetylsalicylic acid (Fast release Aspirin, BAY1019036)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 514 participants |
| Start Date | 2010-04-28 |
| Est. Completion | 2010-07-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01117636
The ClinicalTrials.gov registry entry for NCT01117636 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 514 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01117636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01117636 about?
NCT01117636 is a clinical study titled "Evaluate Analgesic Efficacy of Fast Release Aspirin". The objective of the study is to evaluate the analgesic efficacy of a single, oral dose of fast release aspirin tablets, 1000 mg (2 x 500 mg) compared to regular aspirin tablets, 1000 mg (2 x 500 mg) and placebo in subjects with postsurgical dental pain.
What is the current status of trial NCT01117636?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 514 participants. The study started on 2010-04-28. Estimated completion is 2010-07-07.
What interventions are being tested in trial NCT01117636?
The interventions under investigation include: Placebo (DRUG), Acetylsalicylic Acid (Aspirin, BAYE4465) (DRUG), Acetylsalicylic acid (Fast release Aspirin, BAY1019036) (DRUG).
Who is sponsoring clinical trial NCT01117636?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.